Global Retirement Partners LLC Sells 479 Shares of Zoetis Inc. (NYSE:ZTS)

Global Retirement Partners LLC trimmed its position in Zoetis Inc. (NYSE:ZTS) by 15.1% in the 4th quarter, Holdings Channel.com reports. The institutional investor owned 2,695 shares of the company’s stock after selling 479 shares during the quarter. Global Retirement Partners LLC’s holdings in Zoetis were worth $439,000 as of its most recent SEC filing.

A number of other institutional investors have also added to or reduced their stakes in ZTS. Bank of Jackson Hole Trust purchased a new stake in shares of Zoetis during the 4th quarter worth $641,000. Callahan Advisors LLC grew its stake in Zoetis by 90.4% during the 4th quarter. Callahan Advisors LLC now owns 13,105 shares of the company’s stock valued at $2,135,000 after purchasing an additional 6,221 shares during the last quarter. Kentucky Retirement Systems Insurance Trust Fund increased its holdings in Zoetis by 32.0% in the 4th quarter. Kentucky Retirement Systems Insurance Trust Fund now owns 17,707 shares of the company’s stock worth $2,885,000 after buying an additional 4,293 shares during the period. BKM Wealth Management LLC raised its holdings in shares of Zoetis by 7.5% during the fourth quarter. BKM Wealth Management LLC now owns 8,393 shares of the company’s stock worth $1,367,000 after purchasing an additional 584 shares during the last quarter. Finally, Kestra Investment Management LLC lifted its holdings in shares of Zoetis by 106.9% in the 4th quarter. Kestra Investment Management LLC now owns 6,057 shares of the company’s stock valued at $987,000 after buying an additional 3,129 shares during the period. Hedge funds and other institutional investors own 92.80% of the company’s stock.

Zoetis Price Performance

ZTS stock opened at $160.39 on Monday. The business has a 50 day moving average price of $166.51 and a 200 day moving average price of $177.94. The company has a quick ratio of 1.08, a current ratio of 1.75 and a debt-to-equity ratio of 1.09. The stock has a market cap of $71.82 billion, a price-to-earnings ratio of 29.32, a PEG ratio of 2.78 and a beta of 0.90. Zoetis Inc. has a fifty-two week low of $144.80 and a fifty-two week high of $200.53.

Zoetis (NYSE:ZTS) last issued its quarterly earnings data on Thursday, February 13th. The company reported $1.40 earnings per share for the quarter, topping the consensus estimate of $1.37 by $0.03. The business had revenue of $2.32 billion during the quarter, compared to the consensus estimate of $2.30 billion. Zoetis had a net margin of 26.86% and a return on equity of 53.82%. Equities research analysts anticipate that Zoetis Inc. will post 6.07 earnings per share for the current fiscal year.

Zoetis Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 3rd. Shareholders of record on Monday, April 21st will be issued a dividend of $0.50 per share. This represents a $2.00 annualized dividend and a dividend yield of 1.25%. The ex-dividend date is Monday, April 21st. Zoetis’s payout ratio is 36.56%.

Insider Transactions at Zoetis

In other Zoetis news, EVP Roxanne Lagano sold 326 shares of the stock in a transaction that occurred on Tuesday, February 11th. The stock was sold at an average price of $171.18, for a total transaction of $55,804.68. Following the completion of the sale, the executive vice president now directly owns 16,107 shares of the company’s stock, valued at approximately $2,757,196.26. This trade represents a 1.98 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 0.16% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts have weighed in on ZTS shares. UBS Group began coverage on shares of Zoetis in a research report on Monday, December 9th. They issued a “neutral” rating and a $196.00 price objective for the company. Morgan Stanley decreased their price target on shares of Zoetis from $243.00 to $238.00 and set an “overweight” rating on the stock in a research note on Friday, February 14th. Stifel Nicolaus dropped their target price on Zoetis from $210.00 to $180.00 and set a “buy” rating for the company in a report on Tuesday, January 7th. Barclays increased their price objective on Zoetis from $242.00 to $244.00 and gave the stock an “overweight” rating in a research report on Friday, February 14th. Finally, Piper Sandler reduced their price target on shares of Zoetis from $210.00 to $200.00 and set an “overweight” rating on the stock in a research note on Monday, February 10th. One research analyst has rated the stock with a hold rating, nine have given a buy rating and two have issued a strong buy rating to the company’s stock. According to MarketBeat.com, Zoetis presently has a consensus rating of “Buy” and a consensus target price of $215.40.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.